Antonarakis ES et al. Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199. Genitourinary Cancers Symposium 2019;Abstract 216.
Armstrong AJ et al. Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. Genitourinary Cancers Symposium 2019;Abstract 687.
Cohen R et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol 2018;[Epub ahead of print]. Abstract
De Giorgi U et al. A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy. Genitourinary Cancers Symposium 2019;Abstract 185.
Fizazi K et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration resistant prostate cancer (nmCRPC). Genitourinary Cancers Symposium 2019;Abstract 140.
Fizazi K et al. Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). Genitourinary Cancers Symposium 2019;Abstract 141.
Hofman MS et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19(6):825-33. Abstract
Karzai F et al. A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. Proc ASCO 2018;Abstract 163.
Marin M et al. ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients. Genitourinary Cancers Symposium 2019;Abstract 207.
Marshall CH et al. Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations. Genitourinary Cancers Symposium 2019;Abstract 154.
Parker C et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23. Abstract
Saad F et al. Association between urinary, bowel, and hormonal treatment-related symptoms and clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC): PROSPER study. Genitourinary Cancers Symposium 2019;Abstract 233.
Sartor AO et al. A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223. Genitourinary Cancers Symposium 2019;Abstract 180.
Scher HI et al. Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2019;Abstract 143.
Sharma P et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). Genitourinary Cancers Symposium 2019;Abstract 142.
Small EJ et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). Genitourinary Cancers Symposium 2019;Abstract 144.
Smith M et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):408-19. Abstract
Smith MR et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. Genitourinary Cancers Symposium 2019;Abstract 202.
Smith MR et al; SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408-18. Abstract
Yu EY et al. KEYNOTE-365 Cohort A: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2019;Abstract 145.